(ITOS) Iteos Therapeutics - Ratings and Ratios

Iteos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company, specializes in developing innovative immuno-oncology therapies to treat cancer. The companys lead product candidate, belrestotug, is an anti-TIGIT antibody currently in a Phase 1b clinical trial. Belrestotug works by engaging the Fc gamma receptor to activate immune cells such as dendritic cells, natural killer cells, and macrophages, enhancing antibody-dependent cellular cytotoxicity (ADCC). Additionally, Iteos is advancing inupadenant, a next-generation A2AR antagonist, in Phase 1/2a clinical trials to counteract adenosine-mediated immunosuppression in the tumor microenvironment. The company is also developing EOS-984, a small molecule targeting ENT1 to inhibit adenosines immunosuppressive effects and restore immune cell function, currently in Phase 1 clinical trials. Since its founding in 2011, Iteos has established its headquarters in Watertown, Massachusetts.

Based on the provided data, here is a 3-month forecast for Iteos Therapeutics Inc. (NASDAQ:ITOS):

Over the next three months, ITOS is expected to face headwinds as it currently trades below its 20, 50, and 200-day moving averages (SMA 20: 7.37, SMA 50: 7.54, SMA 200: 11.84), indicating bearish momentum. The stocks average trading volume (20d: 256,853) and low ATR (0.30) suggest limited volatility. The companys fundamental outlook, with a P/B ratio of 0.43 and negative RoE (-19.19), reflects undervaluation and financial losses, which may weigh on investor sentiment. However, with a forward P/E of 12.56 and a market cap of $270.72M, ITOS could see upside if its pipeline progresses positively.